EGFR and lung adenocarcinoma: Brain metastases (BMs) occurred in 25-50% of non-small-cell lung cancer (NSCLC) patients (1, 2), 30-60% of those had epidermal growth factor receptor (EGFR) activating mutation lung adenocarcinoma (LADC) (3, 4).